By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On December 28, 2023, CytoSorbents (NASDAQ:CTSO) announced an update on the initial data analysis of the primary safety and ...

WOBURN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic ...